Antibiotic susceptibility and toxins production of staphylococcus aureus isolated from clinical samples from benin

African Journal of Microbiology Research

Volumn 5, Issue 18, 2011, Pages 2797-2803

  Sina, H ^a   Baba Moussa, F ^b   Ahoyo, T A ^a   Mousse, W ^a   Anagonou, S ^c   Gbenou, J D ^d   Prevost G ^e   Kotchoni, S O ^f   Baba Moussa, L ^a  

^a UNIVERSITY OF ABOMEY CALAVI   (Benin)

^b Faculte des Sciences et Techniques   (Benin)

^c Laboratoires Parasitol Bacteriol   (Benin)

^d FAST Univ d'Abomey Calavi   (Benin)

^e UNIVERSITÉ DE STRASBOURG   (France)

^f RUTGERS UNIVERSITY   (United States)

Author keywords

Antibiotic; Benin; Infection; Methicillinresistant staphylococcus aureus (MRSA); Panton valentine leukocidin (PVL); Staphylococcus aureus

Indexed keywords

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 85036359218     PISSN: None     EISSN: 19960808     Source Type: Journal    
DOI: 10.5897/AJMR11.782     Document Type: Article

References (39)

1. Ayliffe GA (1997). The progressive intercontinental spread of methicillinresistant Staphylococcus aureus. Clin. Infect. Dis., 24: 74-79.
2. Baba-Moussa L, Anani L, Scheftel JM, Couturier M, Riegel P, Haikou N, Hounsou F, Monteil H, Sanni A, Prevost G (2008). Virulence factors produced by strains of Staphylococcus aureus isolated from urinary tract infections. J. Hosp. Infect., 68: 32-38.
3. Baba-Moussa L, Sanni A, Dagnra AY, Anagonou S, Prince-David M, Edoh V, Befort JJ, Prévost G, Monteil H (1999). Approche épidémiologique de l'antibiorésistance et de la production de leucotoxines par les souches de Staphylococcus aureus isolées en Afrique de l'Ouest. Med. Mal. Infect., 29: 689-696.
4. Bell JM, Turnidge JD (2002). High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia- Pacific and South Africa: results from -SENTRY antimicrobial surveillance program, 1998-1999. Antimicrob. Agents. Chemother., 46:879-881.
5. Chambers HF (1997). Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev., 10: 781-791.
6. Couppie P, Cribier B, Prevost G (1994). Leukocidin from Staphylococcus aureus and cutaneous infections: an epidemiologic study. Arch. Dermatol., 130: 1208-1209.
7. Couppie P, Sainte-Marie D, Prevost G, Gravet A, Clyti E, Moreau B, Monteil H, Pradinaud R (1998). Impetigo in French Guyana. A clinical, bacteriological, toxicological and sensitivity to antibiotics study. Ann Dermatol. Venerol., 125: 688-693.
8. Dauwalder O, Lina G, Durand G (2008). Epidemiology of invasive methicillin-resistant Staphylococcus aureus clones collected in France in 2006 and 2007. J. Clin. Microbiol., 46:3454-3458.
9. Denton M, O'Connell B, Bernard P, Jarlier V, Williams Z, Henriksen AS (2008). The EPISA study: antimicrobial susceptibility of Staphylococcus aureus causing primary or secondary skin and soft tissue infections in the community in France, the UK and Ireland. J. Antimicrob. Chemother., 61: 586-588.
10. Deresinski S (2005). Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis., 40: 562-573.
11. Diekema DJ, Beach ML, Pfaller MA, Jones RN (2001). Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. Clin. Microbiol. Infect., 7: 152-157.
12. Diekema DJ, Beekmann SE, Chapin KC, Morel KA, Munson E, Doern GV (2003). Epidemiology and Outcome of Nosocomial and Community-Onset Bloodstream Infection J. Clin. Microbiol., 41: 3655-3660.
13. Durand G, Bes M, Meugnier H, Enright MC, Forey F, Liassine N (2006). Detection of New Methicillin-Resistant Staphylococcus aureus Clones Containing the Toxic Shock Syndrome Toxin 1 Gene Responsible for Hospital- and Community-Acquired Infections in France. J. Clin. Microbiol., 44: 847-853.
14. Durupt F, Mayor L, Bes M, Reverdy ME, Vandenesch F, Thomas L, Etienne J (2007). Prevalence of Staphylococcus aureus toxins and nasal carriage in furuncles and impetigo. Br. J. Dermatol., 157:1161- 1167.
15. Elazhari M, Saile R, Dersi N, Timinouni M, Elmalki A, Zriouil SB, Hassar M, Zerouali K (2009). Activité de 16 Antibiotiques vis-à-vis des Staphylococcus aureus communautaires à Casablanca (Maroc) et Prévalence des Souches Résistantes à la Méthicilline. Eur. J. Sc. Res., 30: 128-137.
16. Fluit AC, Schmitz FJ, Verhoef J (2001). Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Eur. J. Clin. Microbiol., Infect. Dis., 20: 188-191.
17. Foster TJ, Höök M (1998). Surface proteins adhesins of Staphylococcus aureus. Trends Microbiol., 6: 484-488.
18. Fridkin S, Hageman J, Morrison M, Sanza L, Como-Sabetti K, Jernigan J (2005). Methicillin-Resistant Staphylococcus aureus Disease in Three Communities. New Engl. J. Med., 352: 1436-1444.
19. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ (2002). Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann. Intern. Med., 137: 791-797.
20. Gravet A, Baba-Moussa L, Werner S (1998). Characterization of a novel 30% distributed staphylococcal leucotoxin and structure comparison with the other members of the toxin family. Zen. für bakt., pp.401- 402.
21. Gravet A, Couppie P, Meunier O, Clyti E, Moreau B, Pradinaud R, Monteil H, Prevost G (2001). Staphylococcus aureus isolated in cases of impetigo produces both epidermolysin A or B and LukELukD in 78% of 131 retrospective and prospective cases. J. Clin. Microbiol., 39: 4349-4356.
22. Hayanga A, Okello A, Hussein R, Nyong'o A (1997). Experience with methicillin resistant Staphylococcus aureus at the Nairobi Hospital. East Afr. Med. J., 74: 203-204.
23. Ho PL, Cheung C, Mak, GC, Tse CW, Ng TK, Cheung CH (2007). Molecular epidemiology and household transmission of communityassociated méthicilline-resistant Staphylococcus aureus in Hong Kong. Diagn. Microbiol. Infect., 57:145-151.
24. Jevons MP (1961). Celbenin-resistant staphylococci. Br. Med. J., 1: 124-125.
25. Kesah C, Ben Redjeb S, Odugbemi TO (2003). Prevalence of methicillin-resistant Staphylococcus aureus in eight African hospitals and Malta. Clin. Microbiol. Infect., 9: 153-156.
26. Kim HB, Jang HC, Nam HC, Lee YS, Kim BS, Park WB (2004). In vitro activities of 28 antibacterial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: a nationwide survey. Antimicrob. Agents Chemother., 48: 1124-1127.
27. Klugman KP (1998). Emerging infectious diseases-South Africa. Emerg. Infect. Dis. 4: 517-520.
28. Kuehnert MJ, Kruszon-Moran D, Hill HA, McQuillan G, McAllister SK, Fosheim LK, McDougal LK, Chaitram J, Jensen B, Fridkin SK, Killgore G, Tenover FC (2006). Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J. Infect. Dis., 193: 172-179.
29. Makoutodé M, Ahoyo T, Ahossi C (1994). Épidémiologie des infections des plaies opératoires à Staphylococcus aureus au CNHU de Cotonou: aspects bactériologiques. Med. Mal. Infect., 24: 69-79.
30. McBean M, Rajamani S (2001). Increased rates of hospitalization due to septicemia in the US elderly population, 1986-1997. J. Infect. Dis., 183: 596-603.
31. McDonald P, Mitchell E, Johnson H, Rossney A, Humphreys H, Glynn G, Burd M, Doyle D, McDonnell R (2003). Epidemiology of MRSA: the North/South study of MRSA in Ireland 1999. J. Hosp. Infect., 54: 130-134.
32. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O'Boyle C, Danila RN, Lynfield R (2003). Comparison of community- and health careassociated methicillin-resistant Staphylococcus aureus infection. JAMA., 290: 2976-2984.
33. Nauciel C, Vilde JL (2005). Bactériologie Médicale, 2éme ed. Paris: Masson: Masson. pp. 49-58.
34. O'Brien FG, Coombs GW, Pearson JC, Christiansen KJ, Grubb WB (2005). Type V Staphylococcal Cassette Chromosome mec in Community Staphylococci from Australia. Antimicrob. Agents Chemother., 49: 5129-5132
35. Randrianirina F, Soares JL, Ratsima E, Carod JF., Combe P, Grosjean P, Richard V, Talarmin A (2007). In vitro activities of 18 antimicrobial agents against Staphylococcus aureus isolates from the Institut Pasteur of Madagascar. Ann. Clin. Microbiol. Antimicrob., 6: 5.
36. Shittu AO, Lin J (2006). Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in KwaZulu-Natal province, South Africa. BMC Infect. Dis., 6: 125.
37. Sow AI, Fall MI, Boye CS, Gaye-Diallo A, Diop D, Cisse MF, Mboup S, Samb A (1993). Surveillance de la sensibilité aux antibiotiques des souches de Staphylococcus aureus isolées en situation pathogène au chu de Dakar: sécrétion de pénicillinase, résistance hétérogène. Med. Afr. Noire., 40: 407-413.
38. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Hefferman H (2003). Communityacquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg. Infect. Dis., 9: 978-984.
39. Zetola N, Francis GS, Nuermberger EL, Bishai WR (2005). Communityacquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet. Infect. Dis., 5: 275-286.